Key facts
- This page summarizes James Bligh's Form 4 filing for CONDUIT PHARMACEUTICALS INC. (CDT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 20 Nov 2024, 16:30.
James Bligh - 18 Nov 2024 Form 4 Insider Report for CONDUIT PHARMACEUTICALS INC. (CDT)
- Reporting relationship
- Interim CFO, Director
- Issuer ticker
- CDT
- Reported as of
- 18 Nov 2024
- Net transaction value
- +$173,691
- SEC form
- 4
- Accepted by SEC
- 20 Nov 2024, 16:30:06 UTC
- Prior SEC filing
- 11 Jun 2024
- Next SEC filing
- 19 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Bligh
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James Bligh filed Form 4 for CONDUIT PHARMACEUTICALS INC. (CDT) on 20 Nov 2024.
Change
- Previous filing in this sequence was filed on 11 Jun 2024.
- Current net transaction value: +$173,691.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CDT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $173,691
- Shares
- +1,890,000
- Change %
- Price
- $0.0919
- Shares after
- 1,890,000
- Date
- 18 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,890,000
- Exercise price
- $0.0919
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents Options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan.
Footnote F2
The Options vest as follows: (i) 50% on the grant date and (ii) 50% in equal annual installments on the first three anniversaries of the grant date.